General Gastro News Articles
Gastro
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?


Article ID

Home
General Gastro
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Gastro
        Basic Science/Genetics
        Biliary System/Pancreas
        Colorectal Cancer/Polyps
        Economics of Medicine
        Endoscopy
        Esophagus
        GERD/Stomach
        GI Bleeding
        GI Infectious Disease
        GI Motility
        GI Oncology
        Hepatology
        Inflammatory Bowel Dz
        Obesity
        Parenteral/Ent Nutrition
        Peds Gastroenterology
        Pharmacology/kinetics
        Popular Press
        Radiology/Diagnostics
        Small/Large Intestine
        Transplant
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
Top Ten Searches
esophageal  esophageal
probiotics  probiotics
bile duct  bile duct
hepatotoxicity  hepatotoxicity
dyspepsia  dyspepsia
colonoscopy  colonoscopy
helicobacter  helicobacter
hemochromatosis  hemochromatosis
colitis  colitis
resection  resection
 
Sponsor
MDLinx Email Article

To email this article, enter your own "From Email" address,
the recipient's "To Email" address, and click the "Send Email" button.
You may send to up to 5 email addresses.
*From Email:  
*To Email:  
To Email:  
To Email:  
To Email:  
To Email:  
Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors
Fiore M et al. - In unresectable or locally advanced gastrointestinal stromal tumor (GISTs), preoperative imatinib mesylate (IM) is a useful tool both to improve resectability and reduce surgical morbidity.

Methods
  • Aim was to investigate the effect of preoperative IM in pts with unresectable or locally advanced primary GIST
  • From Jan 2003 to Jan 2008, all pts affected by bulky localized GIST were considered for preoperative IM with cytoreductive intent
  • Clinical, pathological and molecular characteristics were assessed and the rate of response recorded
  • Progression-free survival (PFS) was calculated according to Kaplan–Meier analysis

Results
  • 15 pts: 1 esophageal, 7 gastric, 3 duodenal, 4 rectal GISTs received preoperative IM for a median of 9 mo
  • All pts had tumor shrinkage, with a median size reduction of 34%
  • 1 patient had radiological CR
  • In all cases an improvement of the originally planned surgical procedure was obtained:
    • 3 pts initially considered unresectable underwent complete surgery
    • 7 pts with initial indication for extensive surgery were more conservatively operated on
    • 4 pts initially deemed at high perioperative risk underwent safe surgery
  • PFS at 3 yrs from IM onset was 77%
[more...]
Sponsor

Read a Different Specialty

Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Gastroenterology Profession Index

Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2009 MDLinx, Inc.